BioMarin to acquire Amicus Therapeutics for $4.8 billion in rare disease bet
BioMarin Pharmaceutical said on Friday it would acquire Amicus Therapeutics for about $4.8 billion, expanding its presence in rare metabol...
Neutral
0.0